Stem cells treatment of primary torsion dystonia

Primary torsion dystonia (PTD) is a neurological movement disorder characterized by sustained or intermittent involuntary muscle contractions that can cause abnormal movements, repetitive postures, twisting movements, and significant functional limitations. In young patients, primary dystonia can substantially affect mobility, coordination, everyday activities, education, professional development, and quality of life.

Primary torsion dystonia is associated with abnormal motor control within the nervous system. One of the genetically associated forms is DYT1 dystonia, which is linked to pathogenic variants in the TOR1A gene and can present during childhood or adolescence, frequently beginning in a limb.

Conventional management of dystonia may include oral medications, botulinum neurotoxin injections, rehabilitation, and, in selected patients, neurosurgical approaches such as deep brain stimulation (DBS). Treatment is individualized according to the type and severity of dystonia, age, symptoms, functional impairment, and previous response to therapy.

In recent years, stem cell therapy for neurological disorders has attracted increasing scientific interest. Mesenchymal stromal/stem cells (MSCs), particularly umbilical cord-derived MSCs, are being investigated because of their immunomodulatory, paracrine, neurotrophic, and potentially neuroprotective properties.

The following case describes our clinical experience with a patient with primary torsion dystonia and a DYT1 gene mutation who received an investigational cell-based treatment protocol using umbilical cord mesenchymal stromal/stem cells. Stem Cell Therapy in Neurology

Objective of the Treatment

The objective of this clinical observation was to evaluate changes in the clinical manifestations and functional status of a patient with primary torsion dystonia following combined administration of umbilical cord-derived mesenchymal stromal/stem cells.

The treatment protocol included two routes of administration:

• intravenous administration;
• endolumbar administration, meaning administration into the cerebrospinal fluid through a lumbar puncture.

The clinical response was assessed over an extended follow-up period using the Unified Dystonia Rating Scale (UDRS) together with an assessment of the patient's quality of life.

The purpose was to observe whether the treatment was associated with changes in motor dystonia symptoms and functional status over time.

Patient Case: DYT1 Primary Torsion Dystonia

Patient M., born on June 25, 2004, developed symptoms of muscle dystonia approximately eight years before treatment.

The first prominent manifestations were observed particularly in the right hand. Over time, the symptoms became persistent and interfered with the patient's normal motor function.

A comprehensive diagnostic evaluation was performed, including genetic testing. The examination revealed a mutation in the DYT1 gene, and the patient was subsequently diagnosed with primary torsion dystonia.

Conventional conservative treatment did not provide a satisfactory clinical response.

Because of the persistent symptoms and functional impairment, the patient was offered participation in a research program entitled:

“Investigation of the effectiveness of regenerative cell technologies in the neurosurgical treatment of patients with demyelinating diseases of the CNS and cerebral palsy.”

The cell-based treatment was performed within the framework of this research program.

Why Were Umbilical Cord Mesenchymal Stem Cells Used?

Mesenchymal stromal/stem cells (MSCs) are among the most extensively studied cell populations in regenerative medicine.

Umbilical cord-derived MSCs are of particular scientific interest because they can be obtained from donated umbilical cord tissue and expanded under controlled laboratory conditions.

Research into MSC-based regenerative medicine has focused on several biological properties, including:

• immunomodulatory activity;
• paracrine signaling;
• interaction with surrounding cells;
• secretion of growth factors and signaling molecules;
• potential neurotrophic effects;
• potential neuroprotective mechanisms;
• modulation of inflammatory processes;
• support of tissue homeostasis.

Importantly, the proposed mechanism of MSC therapy is not simply that injected cells “replace” damaged neurons.

Modern cell therapy research increasingly focuses on the ability of MSCs to communicate with the patient's tissues through paracrine and cell-signaling mechanisms.

This is particularly relevant to research into stem cell therapy for neurological disorders, neuroregenerative medicine, and cell-based approaches to movement disorders.

Umbilical Cord MSCs and Neuroregenerative Medicine

Umbilical cord mesenchymal stromal/stem cells are being investigated in a range of neurological and regenerative medicine applications.

Researchers are studying whether MSC-derived biological signals can influence the local tissue environment and potentially support processes associated with:

• neuronal survival;
• neurotrophic signaling;
• regulation of inflammatory pathways;
• interaction between neural and immune cells;
• tissue repair mechanisms;
• neurological recovery.

These mechanisms have generated interest in MSC therapy for neurological conditions, including research involving spinal cord disorders, neuroinflammatory diseases, and other neurological conditions.

However, it is important to distinguish biological plausibility and early clinical observations from established clinical efficacy. At present, stem cell therapy is not a universally established treatment for primary torsion dystonia, and larger controlled clinical studies are required to determine its safety, efficacy, optimal cell dose, route of administration, and long-term outcomes. Neural Stem Cells New Therapy for Neuroinflammation

Cell Preparation and Treatment Protocol

For this research protocol, mesenchymal stromal/stem cells were cultured from healthy human umbilical cord tissue.

The cells were prepared according to the minimum criteria specified within the applicable research protocol and internationally recognized criteria for the characterization of mesenchymal stromal/stem cells.

The patient received three administrations of umbilical cord-derived MSCs, with an interval of approximately six months between procedures.

The dose was:

16 × 10⁷ cells per administration.

The treatment protocol incorporated two routes of administration:

1. Intravenous administration of MSCs
2. Endolumbar administration of MSCs

The combined approach was selected as part of the investigational treatment protocol to provide systemic administration while also allowing administration through the cerebrospinal fluid compartment.

Endolumbar Administration of Stem Cells

The endolumbar procedure was performed according to the standard technique used for lumbar puncture.

The procedure was carried out in an operating-room environment with appropriate aseptic and antiseptic precautions and under local anesthesia.

Endolumbar or intrathecal administration is being investigated in some areas of regenerative neurology because it provides a route through which biological products can be delivered into the cerebrospinal fluid.

However, administration into the cerebrospinal fluid is an invasive medical procedure and should only be considered within an appropriate clinical and regulatory framework, with careful patient selection and monitoring.

Clinical Assessment Using the Unified Dystonia Rating Scale

To evaluate changes in motor dystonia, the patient's condition was assessed using the Unified Dystonia Rating Scale (UDRS).

The UDRS is a clinical tool used to quantify the severity and functional impact of dystonia.

Before treatment, the patient's motor dystonia score was:

15 points.

Following treatment, the score progressively decreased during follow-up:

Follow-Up Period	UDRS Score	Change Compared with Baseline
Before treatment	15	Baseline
6 months	13	Improvement
12 months	10	Further improvement
18 months	7	Continued improvement
24 months	4	Marked improvement

The observed decrease in the UDRS score was accompanied by a reported improvement in the patient's functional status and quality of life.

The progressive nature of the improvement over the observation period was considered clinically significant within the context of this individual case.

Nevertheless, because this was an individual clinical observation without a control group, the results cannot establish that MSC therapy was solely responsible for the improvement.

Reported Clinical Improvement

Following the administration of umbilical cord MSCs, the patient's dystonia symptoms gradually decreased.

The UDRS score declined from 15 points at baseline to 4 points at 24 months.

This improvement was accompanied by a positive change in the patient's quality of life.

The clinical observation suggests that the patient experienced improvement in motor manifestations of primary torsion dystonia during the follow-up period.

The long-term observation is particularly relevant because neurological disorders such as dystonia require sustained monitoring. A single short-term assessment cannot determine whether an observed change represents a temporary response or a longer-lasting clinical improvement.

Possible Mechanisms of MSC Therapy in Dystonia

The mechanisms through which mesenchymal stromal/stem cells could potentially influence neurological conditions remain under investigation.

Several biological mechanisms have been proposed.

Paracrine Signaling

MSCs can release biologically active molecules and extracellular vesicles that participate in communication between cells.

These signaling mechanisms may influence the surrounding tissue environment and are one of the principal areas of interest in modern cell-based regenerative medicine.

Neurotrophic Effects

MSCs have been investigated for their ability to influence neurotrophic signaling.

Neurotrophic factors are involved in neuronal survival, growth, differentiation, and communication.

This potential neurotrophic activity is one reason MSCs are being studied in neuroregenerative medicine.

Immunomodulatory Effects

MSCs can interact with components of the immune system and influence inflammatory signaling pathways.

Because neuroinflammation and immune-mediated mechanisms are being investigated in various neurological diseases, the immunomodulatory properties of MSCs are of considerable scientific interest. Stem Cell Treatment Abroad: An International Clinic with Advanced Regenerative Medicine Solutions

Neuroprotective Potential

Experimental studies have explored whether MSC-derived factors may create a tissue environment that supports neuronal survival and reduces cellular stress.

However, these mechanisms remain subjects of ongoing research and should not be interpreted as proof that MSCs can regenerate or replace dysfunctional neuronal circuits responsible for dystonia.

Why Is This Case Important?

Primary torsion dystonia can be particularly challenging when symptoms begin at a young age and do not respond adequately to conventional conservative treatment.

The case described here is notable because:

• the patient developed symptoms at a young age;
• genetic testing identified a DYT1-associated mutation;
• conventional conservative treatment was not sufficiently effective;
• an investigational regenerative medicine protocol was used;
• the treatment included umbilical cord-derived MSCs;
• three administrations were performed at six-month intervals;
• both intravenous and endolumbar routes were used;
• clinical assessment continued for 24 months;
• the UDRS score decreased from 15 to 4 points;
• an improvement in quality of life was reported.

These observations provide a basis for further investigation but cannot by themselves establish the effectiveness of stem cell therapy for primary torsion dystonia.

Stem Cell Therapy for Dystonia: Current Research Perspective

Interest in stem cell therapy for dystonia is part of the broader development of regenerative neurology.

Researchers are investigating several different cell-based strategies for neurological diseases. These approaches may involve different cell types, routes of administration, treatment schedules, and biological mechanisms.

For dystonia specifically, it is essential to distinguish between experimental regenerative approaches and established treatments.

Current standard management can include medication, botulinum toxin for appropriate focal symptoms, rehabilitation, and deep brain stimulation in selected patients. The suitability of each approach depends on the individual diagnosis and clinical presentation.

The case presented here therefore represents an individual clinical experience that may contribute to further research rather than a guarantee of therapeutic response.

The Importance of Long-Term Follow-Up

Long-term follow-up is particularly important in regenerative medicine.

A patient may experience changes in symptoms for many different reasons, including natural disease variation, rehabilitation, medications, lifestyle changes, placebo effects, or other interventions.

For this reason, clinical research requires systematic assessment over time.

In this case, the patient was followed for 24 months, and the UDRS score was recorded at multiple time points.

The progressive reduction from 15 points before treatment to 4 points at 24 months provides an objective clinical measure of change within this individual patient.

Future research should include larger patient populations, standardized outcome measures, control groups, longer follow-up, and appropriate statistical analysis.